Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14965231 | 0.89 | HPGD (0.50) | RECQLKDM4EPKMGPR119HPGD | |
| SCHEMBL6157453 | 0.86 | USP2 (0.60) | RECQLUSP2SMN1; SMN2THRBKDM4E | |
| SCHEMBL8892846 | 0.85 | RECQL (0.56) | RECQLUSP2SMN1; SMN2THRBPKM | |
| SCHEMBL77972 | 0.82 | RECQL (0.56) | RECQLUSP2SMN1; SMN2THRBGPR119 | |
| SCHEMBL1088712 | 0.82 | USP2 (0.62) | RECQLUSP2SMN1; SMN2THRBKDM4E | |
| SCHEMBL16293342 | 0.81 | HPGD (0.45) | KDM4EPKMGPR119HPGDMAPT | |
| SCHEMBL27121409 | 0.81 | DDB1 (0.41) | USP2SMN1; SMN2HPGDMAPT | |
| SCHEMBL17275941 | 0.81 | RECQL (0.61) | RECQLUSP2SMN1; SMN2THRBGPR119 | |
| SCHEMBL21998064 | 0.80 | HPGD (0.48) | RECQLUSP2SMN1; SMN2KDM4EPKM | |
| SCHEMBL15353080 | 0.80 | SMN1; SMN2 (0.72) | RECQLUSP2SMN1; SMN2THRBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290511-B2 | Thieno-pyrimidines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2016-03-22 | — | — | US | disclosed |
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | KCNA3, KCNJ1, KCNJ11 | RECQL 402/4885USP2 4827/4885SMN1; SMN2 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.